Hikma Pharmaceuticals plc reiterated its ambitions to tap into the “growth of the biosimilar market in the US” as it announced an agreement worth up to $150m to in-license Bio-Thera Solutions’ BAT2206 biosimilar ustekinumab candidate, with the race to compete with Johnson & Johnson’s Stelara autoimmune disorders blockbuster continuing to heat up.
Under terms of the agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206, which is currently undergoing global Phase III clinical trials; while Hikma
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?